News | Radiation Therapy | February 06, 2023

Achieves CE mark for Halcyon and Ethos radiotherapy systems featuring HyperSight 

Achieves CE mark for Halcyon and Ethos radiotherapy systems featuring HyperSight

February 6, 2023 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as CE mark, for Halcyon and Ethos radiotherapy systems featuring Varian's HyperSight imaging solution. On February 1, a cancer patient at Penn Medicine became the first person in the world to be treated on a Halcyon system equipped with HyperSight. 

HyperSight enables clinicians to capture high-quality images of patients during their daily radiation treatments. These images are used for daily localization of patient tumors, and HyperSight now enables them to be used for replanning and adaptation to patient and tumor changes. HyperSight's cone-beam computed tomography (CBCT) technology delivers larger images with better contrast, and is 10 times faster than conventional linear accelerator-based imaging systems, saving time for patients and creating the potential to significantly enhance the patient experience. 

Traditional CBCT imaging can take up to 60 seconds and may require patients with tumors that move with breathing — including lung, liver, and left breast tumors — to hold their breath several times to acquire a full, clear image. HyperSight can acquire images in six seconds, potentially minimizing patient discomfort and anxiety and contributing to clearer images due to reduction of motion related image blurring. 

The quantitative information about patient anatomy (Hounsfield Units) contained within HyperSight images allows, for the first time, for radiation dose distributions to be calculated directly on CBCT images. This calculation previously required a patient to make an additional trip to a separate CT scanner used for treatment simulation and planning. With HyperSight, this calculation can be performed directly on the linac-based CBCT image during the normal course of treatment. As a result, this technology may help adapt treatment to adjust to anatomical changes to the tumor and surrounding organs, which can change from day to day during treatment. 

"Varian has long been focused on pioneering innovations that can enhance the radiotherapy experience and outcomes for both patients and cancer care teams. Becoming a Siemens Healthineers company has given us an opportunity to sharpen and accelerate these efforts, with a focus on connecting the power of imaging inside and outside the treatment room," said Kevin O'Reilly, President of Radiation Oncology Solutions at Varian. "HyperSight reflects the power of our expanded view of the patient journey and robust imaging technology. We look forward to working with our clinical partners and the broader radiotherapy community to drive adoption and further advancement of this technology, as we continue our work to transform the patient pathway and deliver on our mission to create a world without fear of cancer." 

As a longtime collaborator and the first cancer center in the world to adopt Varian's Halcyon system, Penn Medicine has played a key role in supporting the advancement of radiation therapy innovations, including HyperSight. 

"Bringing this technology to patients is another step forward in our work to help develop and assess cutting-edge treatment technologies that improve care for cancer patients," said James Metz, MD, chair of Radiation Oncology and leader of the Roberts Proton Therapy Center at Penn. 

For more information: www.varian.com


Related Content

News | Artificial Intelligence

March 17, 2023 — A new paper published in the Journal of Medical Internet Research describes how generative models such ...

Time March 17, 2023
arrow
News | Quality Assurance (QA)

March 16, 2023 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery ...

Time March 16, 2023
arrow
News | Lung Imaging

March 15, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Time March 15, 2023
arrow
News | Radiation Oncology

March 14, 2023 — Elekta announced that is has signed a joint venture with China National Pharmaceutical Group Co., Ltd. ...

Time March 14, 2023
arrow
News | Digital Pathology

March 13, 2023 — Proscia, a leading provider of digital and computational pathology solutions, today announced that ...

Time March 13, 2023
arrow
News | Artificial Intelligence

March 10, 2023 — Computed tomography (CT) is one of the most powerful and well-established diagnostic tools available to ...

Time March 10, 2023
arrow
Feature | Radiology Business | By Christine Book

With an increasing focus on personalizing the patient experience and enhancing communication between radiologists and ...

Time March 10, 2023
arrow
News | Digital Pathology

March 7, 2023 — Proscia, a leading provider of digital and computational pathology solutions, today announced that ...

Time March 07, 2023
arrow
News | ARRS

March 6, 2023 — The American Roentgen Ray Society (ARRS) proudly recognizes the following four radiologists, as well as ...

Time March 06, 2023
arrow
News | Radiation Oncology

March 3, 2023 — RefleXion Medical, Inc., a therapeutic oncology company, announced the installation of its RefleXion X1 ...

Time March 03, 2023
arrow
Subscribe Now